In brief

Focused on the development of novel medicines to validated anti-cancer and fibrosis targets in areas of unmet need

Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner. The company’s product development strategy has three interrelated components:

Cancer: RXC004 (Porcupine Inhibitor), our lead clinical asset

• RXC004 Phase 1 monotherapy dose-escalation study completing in H1 2020 building on compelling animal efficacy data
• Targeted at tumours driven by Wnt pathway in multiple cancers – both monotherapy and immuno-oncology combination designed
• Therapeutic window for class now evident (120+ patients in clinical trials) with early signs of efficacy in selected patients

Fibrosis: Take promising anti-fibrotic portfolio into the clinic. Key promising anti-fibrotic programmes that Redx Pharma has in the pipeline are:

• ROCK2 RXC007: IPF, Non-alcoholic steatohepatitis (NASH), CKD
• Porcupine RXC006: Idiopathic pulmonary fibrosis (IPF)
• GI-targeted ROCK: Crohn’s Disease-related fibrosis

Research: Next generation therapies

• Preclinical programmes to generate novel development compounds in 18-36 months through rigorous selection of targets strong medicinal chemistry.